Healthcare conglomerate specializing in pharmaceuticals, medical devices, and consumer health products with trusted global brands.
Profile & Fundamentals
Johnson & Johnson: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Johnson & Johnson Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Company profile record
Johnson & Johnson
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- Johnson & Johnson
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇺🇸 United States
- Head office
- One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Leadership & scale
- Chief executive
- Mr. Joaquin Duato
- CEO year born
- 1963
- Full-time employees
- 138.2K
- Fiscal year end
- December
- IPO date
- 1944-09-24
Fundamentals snapshot
- Market Cap
- USD 621.7B
- P/E
- 29.6x
- Revenue (Q2 26)
- USD 25.3B
- Profit (Q2 26)
- USD 5.5B
- Dividend Yield
- 1.5%
- Revenue (FY 25)
- USD 94.2B
- Shares in public float
- 2.4B
- Insider ownership
- 0.05%
Reporting & identifiers
- Symbol
- JNJ.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US4781601046
- Asset ID
- equity_c3269539-01b8-5845-8971-363e7e618c20
Ownership
Shares Outstanding
Latest: 2.4B | Max: 2.7B | Min: 2.4B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
98.60%
2.4B latest reported shares
Insider Ownership
0.05%
Latest reported insider stake
Short Float
0.01%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 2,684,900,000 |
| 2018-01-01 | 2,724,000,000 |
| 2019-01-01 | 2,669,100,000 |
| 2020-01-01 | 2,669,200,000 |
| 2021-01-01 | 2,670,200,000 |
| 2022-01-01 | 2,663,900,000 |
| 2023-01-01 | 2,430,700,000 |
| 2024-01-01 | 2,427,100,000 |
| 2025-01-01 | 2,439,000,000 |
| 2026-01-01 | 2,440,100,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 213,385,546 | 8.85% | 2026-03-31 |
| Vanguard Capital Management, LLC | 156,605,370 | 6.5% | 2026-03-31 |
| State Street Corp | 133,476,288 | 5.54% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 76,504,870 | 3.17% | 2026-08-31 |
| Vanguard 500 Index Investor | 63,951,090 | 2.65% | 2026-08-31 |
| Vanguard Portfolio Management, LLC | 63,514,436 | 2.64% | 2026-03-31 |
| JPMorgan Chase & Co | 63,096,344 | 2.62% | 2026-03-31 |
| Geode Capital Management, LLC | 59,164,862 | 2.46% | 2026-03-31 |
| Morgan Stanley - Brokerage Accounts | 44,721,167 | 1.86% | 2026-03-31 |
| iShares Core S&P 500 ETF | 32,055,505 | 1.33% | 2026-08-31 |
| NORGES BANK | 31,825,084 | 1.32% | 2026-06-30 |
| State Farm Mutual Automobile Ins Co | 31,590,952 | 1.31% | 2026-06-30 |
| Fidelity 500 Index | 31,127,834 | 1.29% | 2026-07-31 |
| State Street® SPDR® S&P 500® ETF | 29,507,724 | 1.22% | 2026-08-31 |
| Northern Trust Corp | 29,319,669 | 1.22% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The enterprise is demonstrating genuine top-line resilience, with annual revenues surpassing the milestone of one hundred billion dollars behind robust volume growth in flagship oncology medicines and cardiovascular devices. These expanding franchises have effectively absorbed the steep revenue drop in older blockbuster treatments like Stelara following the arrival of low-cost biosimilars. However, reported headline profits continue to be distorted by volatile legal reserves and acquisition amortizations. Beneath these accounting swings, underlying owner earnings are compounding at a stable mid-single-digit pace, backed by around twenty-two billion dollars in reconstructed trailing free cash flow that provides solid foundation for operations.
The enterprise is demonstrating genuine top-line resilience, with annual revenues surpassing the milestone of one hundred billion dollars behind robust volume growth in flagship oncology medicines and cardiovascular devices. These expanding franchises have effectively absorbed the steep revenue drop in older blockbuster treatments like Stelara following the arrival of low-cost biosimilars. However, reported headline profits continue to be distorted by volatile legal reserves and acquisition amortizations. Beneath these accounting swings, underlying owner earnings are compounding at a stable mid-single-digit pace, backed by around twenty-two billion dollars in reconstructed trailing free cash flow that provides solid foundation for operations.
Revenue, Net Income, and Free Cash Flow
Latest: USD 94.2B | Max: USD 94.2B | Min: USD 1.3B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 19x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Operating margins have shown healthy resilience near twenty-seven percent, supported by corporate streamlining following the consumer health spin-off and favorable product mix toward high-margin cancer therapies. Disciplined administrative cost control has helped protect overall profitability despite persistent inflation in hospital labor and specialized supply chains. Looking ahead, maintaining gross margins near sixty-eight percent will become increasingly challenging. Severe biosimilar price discounting on legacy treatments alongside mandatory government Medicare price caps represent structural headwinds that sales volume gains can only partially offset, keeping a tight ceiling on further profit margin expansion.
Operating margins have shown healthy resilience near twenty-seven percent, supported by corporate streamlining following the consumer health spin-off and favorable product mix toward high-margin cancer therapies. Disciplined administrative cost control has helped protect overall profitability despite persistent inflation in hospital labor and specialized supply chains. Looking ahead, maintaining gross margins near sixty-eight percent will become increasingly challenging. Severe biosimilar price discounting on legacy treatments alongside mandatory government Medicare price caps represent structural headwinds that sales volume gains can only partially offset, keeping a tight ceiling on further profit margin expansion.
Profitability Margins
Latest: 67.9% | Max: 70.3% | Min: 1.7%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
67.9%
Gross profit / revenue
Operating Margin
27.2%
Operating income / revenue
Net Margin
28.5%
Net income / revenue
FCF Margin
20.9%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 71,890,000,000 | 16,540,000,000 | 15,541,000,000 |
| 2017-12-31 | 76,450,000,000 | 1,300,000,000 | 17,777,000,000 |
| 2018-12-31 | 81,581,000,000 | 15,297,000,000 | 18,531,000,000 |
| 2019-12-31 | 82,059,000,000 | 15,119,000,000 | 19,918,000,000 |
| 2020-12-31 | 82,584,000,000 | 14,714,000,000 | 20,189,000,000 |
| 2021-12-31 | 78,740,000,000 | 20,878,000,000 | 19,758,000,000 |
| 2022-12-31 | 79,990,000,000 | 17,941,000,000 | 17,185,000,000 |
| 2023-12-31 | 85,159,000,000 | 35,153,000,000 | 18,248,000,000 |
| 2024-12-31 | 88,821,000,000 | 14,066,000,000 | 19,842,000,000 |
| 2025-12-31 | 94,193,000,000 | 26,804,000,000 | 19,698,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 18.83 | Trailing four quarters |
| 2024-12-31 | 24.95 | Trailing four quarters |
| 2023-12-31 | 10.84 | Trailing four quarters |
| 2022-12-31 | 26.23 | Annual net income |
| 2021-12-31 | 21.88 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 69.69 | 29.06 | 23.01 | 21.62 |
| 2017-12-31 | 66.72 | 24.72 | 1.7 | 23.25 |
| 2018-12-31 | 66.79 | 25.96 | 18.75 | 22.71 |
| 2019-12-31 | 66.42 | 25.55 | 18.42 | 24.27 |
| 2020-12-31 | 65.58 | 23.89 | 17.82 | 24.45 |
| 2021-12-31 | 70.28 | 26.6 | 26.52 | 25.09 |
| 2022-12-31 | 69.25 | 26.27 | 22.43 | 21.48 |
| 2023-12-31 | 68.59 | 25.66 | 41.28 | 21.43 |
| 2024-12-31 | 69.07 | 24.94 | 15.84 | 22.34 |
| 2025-12-31 | 67.88 | 27.17 | 28.46 | 20.91 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.